National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology
CHESTERBROOK, Pa., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology as part of Trevena’s ongoing collaboration with the National Institute on Drug Abuse (NIDA).
The presentation, entitled “Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience Research Branch, Intramural Research Program at NIDA. The presentation included data on Trevena compounds TRV130 and TRV734, and highlighted data showing that TRV734 reduced drug-seeking behavior in a rat model of relapse. These data suggest that TRV734 may be a novel, oral maintenance treatment for addiction to opioids or heroin.
“Current therapies, such as methadone and buprenorphine, for patients with opioid abuse disorder have limited or no efficacy for some patients and are associated with substantial safety and tolerability concerns,” said Mark A. Demitrack, M.D., Sr. Vice President and Chief Medical Officer at Trevena. “We are encouraged by the data generated thus far and are pleased to continue our collaboration with NIDA to further investigate the potential use of TRV734 for this important unmet medical need.”
Preclinical studies performed by NIDA scientists suggest that biased mu opioid receptor ligands, like TRV734, may offer an alternative to current opioid maintenance therapies.
TRV734 is a new chemical entity (NCE) targeting the same novel mechanism of action as Trevena’s intravenous (IV) NCE, oliceridine, which selectively stimulates G-protein coupling at the mu-opioid receptor with low beta-arrestin recruitment. TRV734 was designed to be orally available, and its mechanism of action suggests it may offer valuable benefits for two distinct areas of important unmet medical need: acute and chronic pain, and management of opioid dependence associated with opioid use disorder. Trevena is collaborating with NIDA to further evaluate TRV734 for the management of opioid dependence. TRV734 and oliceridine are investigational products not approved by FDA for distribution in the US.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain. The Company has three novel and differentiated drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the treatment of acute migraine, and TRV734 for pain and/or management of opioid dependence. In its preclinical programs, Trevena is evaluating a set of novel S1P modulators that may offer a new, non-opiate approach to managing chronic pain.
Cautionary note on forward looking statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials, including the data presented by NIDA with respect to TRV734 that showed TRV734 reduced drug-seeking behavior in a rat model of relapse and therefore whether TRV734 may be a novel, alternative maintenance treatment for addiction to prescription opioids and heroin and may meet an important unmet need for patients; expectations for regulatory interactions, submissions, or approvals; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
This press release, information, and interpretation of the data is not sanctioned by the American College of Neuropsychopharmacology.
Senior Director, Corporate Strategy & Investor Relations
Released December 13, 2018